Danish Commercial Services Stock News

Earlier this week, Novo Nordisk presented new sub-analyses from its OASIS 4 and STEP UP phase 3 trials at ECO 2026, showing that both oral and high-dose injectable Wegovy produced substantial weight loss and functional improvements in adults with obesity, with safety consistent with the GLP-1 class. The data also indicated that early responders can achieve very large weight reductions, most of the lost weight comes from fat rather than muscle, and oral Wegovy outperformed rival orforglipron...

Dampskibsselskabet Norden (CPSE:DNORD) has drawn attention after reporting Q1 2026 earnings, with sales of US$813.5 million and a sharp drop in net income to US$11.2 million versus US$32.5 million a year earlier. See our latest analysis for Dampskibsselskabet Norden. The Q1 2026 earnings release and the recent ex dividend date have come alongside firm share price momentum, with a 1 month share price return of 12.83% and a 1 year total shareholder return of 60.52%. This suggests recent...

Event context and recent share performance Ørsted (CPSE:ORSTED) has drawn fresh investor attention following its recent share performance, with the stock up around 27% year to date and about 19% over the past 12 months. See our latest analysis for Ørsted. Recent share price moves have been mixed, with a 10.8% 90 day share price return and a 27.0% year to date share price return, in contrast with a 54.1% decline in three year total shareholder return. This suggests momentum has picked up only...

Bavarian Nordic (CPSE:BAVA) has opened 2026 with Q1 revenue of DKK 1,057.8 million and Basic EPS of DKK 0.20, while the trailing twelve months show revenue of DKK 5.96 billion and Basic EPS of DKK 14.86. This sets a clear snapshot of the current run rate. Over recent quarters, revenue has moved from DKK 2,093.9 million in Q4 2024 to DKK 1,346.6 million in Q1 2025 and DKK 1,057.8 million in Q1 2026. Basic EPS shifted from DKK 10.15 to DKK 2.70 and then DKK 0.20. The latest release therefore...

Last week saw the newest half-year earnings release from Coloplast A/S ( CPH:COLO B ), an important milestone in the...

TORM, ticker CPSE:TRMD A, reported a strong Q1 2026 earnings surge. Geopolitical tensions and the closure of the Strait of Hormuz pushed freight rates to record highs. The company upgraded full year guidance and moved ahead with a fleet renewal plan, adding new vessels. TORM focuses on product tankers that transport refined oil products, so freight disruptions and route changes directly affect its earnings power. With key shipping lanes constrained and rerouted, demand for available,...

Investors were disappointed with the weak earnings posted by Netcompany Group A/S ( CPH:NETC ). While the headline...

Unsurprisingly, Zealand Pharma A/S' ( CPH:ZEAL ) stock price was strong on the back of its healthy earnings report. We...

Coloplast (CPSE:COLO B) Q2 2026 earnings in focus Coloplast (CPSE:COLO B) has kicked off its Q2 2026 reporting with Q1 figures that put hard numbers around the story, with revenue at about DKK7.0 billion, basic EPS of DKK6.21 and net income of DKK1.40 billion. These results are backed by trailing 12 month totals of DKK27.9 billion in revenue, DKK17.70 in EPS and DKK4.0 billion in net income. Over recent quarters the company has seen revenue hover in a tight band between DKK6.93 billion and...

Bavarian Nordic (CPSE:BAVA) is back in focus after securing US$97 million in contract options from the U.S. government for freeze dried smallpox vaccines and lifting its full year 2026 financial guidance. See our latest analysis for Bavarian Nordic. At a share price of DKK194.6, Bavarian Nordic has seen a 1-year total shareholder return of 16.84%, while the 5-year total shareholder return is down 28.27%. This suggests that recent momentum has improved compared with a weaker longer term...

We wouldn't blame Dampskibsselskabet Norden A/S ( CPH:DNORD ) shareholders if they were a little worried about the fact...

A week ago, Zealand Pharma A/S ( CPH:ZEAL ) came out with a strong set of first-quarter numbers that could potentially...

We wouldn't blame Danske Bank A/S ( CPH:DANSKE ) shareholders if they were a little worried about the fact that Carsten...

Genmab A/S ( CPH:GMAB ) shareholders are probably feeling a little disappointed, since its shares fell 3.9% to kr.1,642...

Shareholders might have noticed that Ørsted A/S ( CPH:ORSTED ) filed its quarterly result this time last week. The...

Shareholders might have noticed that GN Store Nord A/S ( CPH:GN ) filed its first-quarter result this time last week...

As you might know, Ambu A/S ( CPH:AMBU B ) last week released its latest quarterly, and things did not turn out so...

Shareholders of Pandora A/S ( CPH:PNDORA ) will be pleased this week, given that the stock price is up 12% to kr.541...

Vestas Wind Systems A/S ( CPH:VWS ) just released its quarterly report and things are looking bullish. The company beat...

FLSmidth (CPSE:FLS) has secured significant repeat contracts for a major Banded Hematite Quartzite beneficiation project. The orders cover industry leading technologies, including what is described as the world's largest High Pressure Grinding Roll and several large scale stirred media mills. The equipment package is aligned with FLSmidth's MissionZero ambition, aiming to support more sustainable mining operations. The latest awards add substantial contracted work for the coming years for...

How Zealand Pharma Stock Has Been Performing Zealand Pharma (CPSE:ZEAL) has drawn renewed investor attention after a mixed stretch, with the stock showing gains over the past month but negative moves over the past 3 months, year to date, and the past year. Over the past month, the share price return stands at about 5.8%, while the past 3 months show a decline of around 21.1%. Year to date, the stock is down roughly 31.5%, and the past year reflects a total return decline of about...

Q1 2026 results set the tone for NTG Nordic Transport Group (CPSE:NTG) NTG Nordic Transport Group (CPSE:NTG) opened 2026 with Q1 revenue of DKK 2,983 million and basic EPS of DKK 2.62, framing the latest quarterly read alongside a trailing twelve month EPS of DKK 10.14 on revenue of DKK 11.67 billion. Over the past year, the company has seen revenue move from DKK 9.35 billion in the trailing twelve months to Q4 2024 to DKK 11.67 billion by Q1 2026, while trailing EPS shifted from DKK 13.94 to...

Royal Unibrew (CPSE:RBREW) is back in focus after disclosing that its PepsiCo license agreements for Denmark, Finland, and the Baltic states, currently about 13% of net revenue, will expire at the end of 2028. See our latest analysis for Royal Unibrew. Despite the PepsiCo update and a series of recent announcements, including a larger share buyback, AGM approvals and Q1 2026 results, the stock has had a 30 day share price return of a 19.7% decline and a 1 year total shareholder return of a...

Zealand Pharma and Roche have advanced obesity candidate petrelintide into Phase 3 development. Boehringer Ingelheim reported positive Phase III results for obesity drug survodutide, co-invented with Zealand Pharma. Zealand Pharma is eligible for milestone payments and royalties from survodutide, subject to future sales. CPSE:ZEAL is trading at DKK309.0, with the stock down 32.8% year to date and 36.4% over the past 12 months, alongside gains of 39.1% over three years and 57.4% over five...